509 related articles for article (PubMed ID: 28646014)
41. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
42.
Henkenberens C; VON Klot CA; Ross TL; Bengel FM; Wester HJ; Katja H; Christiansen H; Derlin T
Anticancer Res; 2017 Mar; 37(3):1273-1279. PubMed ID: 28314292
[TBL] [Abstract][Full Text] [Related]
43. Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
Arafa AT; Jain A; Skrobanek P; Humphrey B; Froelich JW; Antonarakis ES
Prostate; 2023 Jun; 83(9):863-870. PubMed ID: 36999911
[TBL] [Abstract][Full Text] [Related]
44.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
Maurer T; Gschwend JE; Rauscher I; Souvatzoglou M; Haller B; Weirich G; Wester HJ; Heck M; Kübler H; Beer AJ; Schwaiger M; Eiber M
J Urol; 2016 May; 195(5):1436-1443. PubMed ID: 26682756
[TBL] [Abstract][Full Text] [Related]
46. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
Calais J; Zhu S; Hirmas N; Eiber M; Hadaschik B; Stuschke M; Herrmann K; Czernin J; Kishan AU; Nickols NG; Elashoff D; Fendler WP
BMC Cancer; 2021 May; 21(1):512. PubMed ID: 33962579
[TBL] [Abstract][Full Text] [Related]
47. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
48. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
49. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
50. Biochemical Recurrence of Prostate Cancer: Initial Results with [
Giesel FL; Will L; Kesch C; Freitag M; Kremer C; Merkle J; Neels OC; Cardinale J; Hadaschik B; Hohenfellner M; Kopka K; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Apr; 59(4):632-635. PubMed ID: 29419475
[TBL] [Abstract][Full Text] [Related]
51.
Sachpekidis C; Bäumer P; Kopka K; Hadaschik BA; Hohenfellner M; Kopp-Schneider A; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):904-912. PubMed ID: 29362859
[TBL] [Abstract][Full Text] [Related]
52. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.
Hijazi S; Meller B; Leitsmann C; Strauss A; Meller J; Ritter CO; Lotz J; Schildhaus HU; Trojan L; Sahlmann CO
Prostate; 2015 Dec; 75(16):1934-40. PubMed ID: 26356236
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
54. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria.
Fanti S; Hadaschik B; Herrmann K
J Nucl Med; 2020 May; 61(5):678-682. PubMed ID: 31806774
[TBL] [Abstract][Full Text] [Related]
55. Impact of
Couñago F; Martínez-Ballesteros C; Artigas C; Díaz-Gavela AA; Gómez LLG; Lillo-García ME; Chicharo JR; Recio M; Maldonado A; Thuissard IJ; Andreu-Vázquez C; Sanz-Rosa D; Conde-Moreno AJ; Marcos FJ; García SS; Martínez-Salamanca JI; Carballido-Rodríguez J; Hornedo J; Cerro ED
Rep Pract Oncol Radiother; 2020; 25(3):405-411. PubMed ID: 32368192
[TBL] [Abstract][Full Text] [Related]
56. Current status of PSMA PET imaging in prostate cancer.
Ho CL; Wu KK; Chen S
Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():7-11. PubMed ID: 32852899
[TBL] [Abstract][Full Text] [Related]
57.
Yasmin T; Younis MN; Ameer K; Farooq A; Shahid A
Pol J Radiol; 2023; 88():e331-e337. PubMed ID: 37576382
[TBL] [Abstract][Full Text] [Related]
58. The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?
Mei R; Farolfi A; Morigi JJ; Fanti S
Curr Opin Urol; 2022 May; 32(3):269-276. PubMed ID: 35552308
[TBL] [Abstract][Full Text] [Related]
59. Restaging the Biochemical Recurrence of Prostate Cancer with [
Fourquet A; Lahmi L; Rusu T; Belkacemi Y; Créhange G; de la Taille A; Fournier G; Cussenot O; Gauthé M
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808301
[TBL] [Abstract][Full Text] [Related]
60. Cancers and Benign Processes on
Ozcan PP; Serdengectı M; Koc ZP; Balcı Y; Tek M; Bozlu M; Akbay E; Erçolak V
World J Nucl Med; 2022 Jun; 21(2):106-111. PubMed ID: 35865153
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
